Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells

• Published in: Molecular carcinogenesis Vol. 52; no. 5; pp. 404 - 411
• Main Authors: Yan, Guang, Graham, Kimmer, Lanza-Jacoby, Susan
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.05.2013; Wiley Subscription Services, Inc
• Subjects: Antineoplastic Combined Chemotherapy Protocols - pharmacology; Apoptosis - drug effects; bcl-2-Associated X Protein - metabolism; bcl-X Protein - metabolism; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Cancer therapies; Cell Cycle Checkpoints - drug effects; Cell Line, Tumor; Cell Survival - drug effects; Cells; curcumin; Curcumin - administration & dosage; Curcumin - pharmacology; Cyclin D1 - metabolism; Enzyme Inhibitors - pharmacology; Female; histone deacetylase inhibitors; Humans; Hydroxamic Acids - administration & dosage; Hydroxamic Acids - pharmacology; Imidazoles - pharmacology; MAP Kinase Kinase 4 - antagonists & inhibitors; MAP Kinase Kinase 4 - metabolism; p38 Mitogen-Activated Protein Kinases - metabolism; Pharmacology; Phosphorylation - drug effects; Proteins; Proto-Oncogene Proteins c-akt - metabolism; Pyridines - pharmacology

Breast cancer patients with HER‐2 positive or estrogen receptor negative tumors have a poor prognosis because these tumors are aggressive and respond poorly to standard therapies. Histone deacetylase (HDAC) inhibitors have been shown to decreased cell survival, which suggests that HDAC inhibitors ma...